Perrigo Company plc
NYSE•PRGO
CEO: Mr. Patrick Lockwood-Taylor
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Listing Date: 1991-12-17
Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
Contact Information
Market Cap
$1.28B
P/E (TTM)
-0.9
35.3
Dividend Yield
12.5%
52W High
$29.08
52W Low
$9.23
52W Range
Rank45Top 56.8%
3.6
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 3.6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q4 2025 Data
Revenue
$1.11B+0.00%
4-Quarter Trend
EPS
-$10.23+0.00%
4-Quarter Trend
FCF
$148.60M+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
Net Sales Decline Net sales $4.25B USD, down 2.8% from prior year; driven by lower Digestive Health and Nutrition sales.
Massive Goodwill Impairment Recognized $1.36B USD goodwill impairment charge, resulting in $(1.12)B USD operating loss for 2025.
Divestitures Reduced Revenue Sales decreased $66.5M USD due to prior year divestitures of Rare Diseases and Hospital & Specialty Businesses.
CSCA Operating Loss Deepens CSCA segment reported $(669.0)M USD operating loss, down from $269.9M USD income in 2024.
Risk Factors
Intense Product Competition Faces competition threatening demand and pricing across all product lines; requires continuous innovation for market share.
Regulatory Compliance Uncertainty Operates in highly regulated industries; inability to meet future requirements could materially affect operating results.
Supply Chain Geopolitical Risks Supply chain disruption from war in Ukraine or Middle East conflicts could materially affect financial condition.
Asset Impairment Sensitivity Goodwill fair value highly sensitive to revenue growth, margins, and discount rates; future impairment possible.
Outlook
Executing Three-S Strategy Anchored by 'Three-S' plan: Stabilizing Americas, Streamlining portfolio, and Strengthening key brand investments.
Operational Cost Reduction Operational Enhancement Program targets $80M to $100M USD run rate cost savings, mostly realized in 2026.
Segment Reporting Transition Transitioning reporting structure from geographic to category-based view starting Q1 2026 for better alignment.
2026 Capital Expenditure Budget Anticipate 2026 capital expenditures between $90M USD and $130M USD, funded by operating cash flows.
Peer Comparison
Revenue (TTM)
$10.31B
$4.25B
$3.31B
Gross Margin (Latest Quarter)
92.8%
89.1%
84.6%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| FOLD | $4.51B | -163.8 | -12.0% | 50.9% |
| SRRK | $4.08B | -12.1 | -145.9% | 26.9% |
| INDV | $3.88B | 18.5 | -98.9% | 29.2% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
2.1%
Moderate Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
75%
Volatile Cash Flow
Deep Research
Next earnings:May 6, 2026
EPS:$0.59
|Revenue:$1.03B
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data